Why cling to zero-sum thinking in the age of AI?
Why cling to zero-sum thinking in the age of AI?
Read moreAI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
Sep 30, 2026
From AI-Powered Chronic Disease Management to "Hardware + AI + Payment," POMDOCTOR Is Building a Broader Digital Healthcare Infrastructure Platform
GUANGZHOU, China - Sept. 30, 2026 - PRLog -- POMDOCTOR LIMITED (N A S D A Q: POM) $POM is entering the final stretch of September with a rapidly developing story centered on one of healthcare technology's most closely watched opportunities: combining artificial intelligence, real-world healthcare data, connected devices, physician resources and payment infrastructure into a more continuous model of patient care.
The company's latest update adds another important layer to that strategy, highlighting continued optimization of its proprietary AI chronic disease management system, expanding applications for real-world data (RWD), and integrated in-hospital and out-of-hospital chronic disease management pilots.
For investors watching the evolving digital-health landscape, POM's recent announcements show a company attempting to move beyond the traditional online healthcare model and toward a more integrated predictive healthcare infrastructure.
The Latest Development: AI + Real-World Data
POMDOCTOR says it has completed multiple rounds of optimization of its AI chronic disease management system using multidimensional real-world healthcare data.
That data can include:
The company's roadmap is designed around capabilities such as risk identification, personalized chronic disease intervention and physician-patient follow-up workflows. Importantly, POM describes the system as a continuing feedback loop: healthcare data generated through patient management can be processed back into the system to refine AI models and support physicians in developing increasingly personalized management strategies.
That creates a potentially significant distinction in POM's strategy. Rather than treating digital healthcare as a single online transaction, the company is working toward an ongoing data-driven relationship between patient, physician and technology.
A Four-Tier Revenue Opportunity Is Taking Shape
POM has also been emphasizing commercialization of its real-world data capabilities.
The company says its RWD initiatives include pharmaceutical real-world studies, evidence-based research cooperation, B2B healthcare data services and chronic disease management collaborations with third-party healthcare institutions.
That matters because RWD can potentially create value across multiple areas of the healthcare ecosystem. Pharmaceutical companies, healthcare providers, researchers and digital-health organizations can all have applications for properly structured healthcare information.
POM has identified pharmaceutical RWS/RWD services as a core value driver within its diversified revenue structure. The opportunity is therefore not limited to patient-facing healthcare services; it potentially extends into data-related commercial applications as well.
"Hardware + AI + Payment" Becomes a Major Theme
One of POMDOCTOR's most recent announcements, dated September 24, takes the strategy another step forward.
The company highlighted what it calls a differentiated "hardware + AI + payment" healthcare infrastructure model, with the goal of integrating continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment and fulfillment into a unified ecosystem.
The significance of this strategy is that POM is attempting to connect multiple pieces of the healthcare journey rather than concentrating on a single service.
Wearable technologies can provide health information. AI can process and analyze that information. Physicians can provide intervention and follow-up. Payment infrastructure can facilitate the financial side of healthcare services.
The company believes that connecting those components could support a more continuous and predictive healthcare model.
U.S. Expansion Adds Another Potential Catalyst
POM's strategy is also becoming increasingly international.
On August 27, the company announced that it had formally begun preparations for entry into the U.S. healthcare market. POM said it had begun recruiting U.S.-based leadership and operational personnel, assessing the U.S. market, developing a local compliance and regulatory framework, advancing product localization and engaging in exploratory discussions with potential U.S. healthcare partners.
The initial strategy is expected to emphasize pilot validation, including potential applications in remote patient monitoring and chronic disease management.
For investors, the U.S. initiative creates another development path to watch as POM works to determine how its technology and healthcare infrastructure could translate into another major healthcare market.
Investor Visibility Is Increasing
POMDOCTOR also participated in the 28th Annual H.C. Wainwright Global Investment Conference in September, with a company presentation made available to investors. The event provided another opportunity for the company to present its strategy and evolving business model to the investment community.
The timing is notable. POM is simultaneously discussing AI optimization, RWD commercialization, U.S. expansion and its broader infrastructure strategy.
That gives investors several distinct areas to monitor as the company moves forward.
Nasdaq Compliance Adds Another Important Piece
Earlier this summer, POMDOCTOR announced that it had regained compliance with Nasdaq's minimum $1.00 bid-price requirement. Nasdaq determined that POM's ADS closing bid price had remained at or above $1.00 for the required 10 consecutive business days from June 25 through July 9, 2026.
The company's ability to regain compliance removed that particular Nasdaq listing issue and allowed management to focus attention on its operating and strategic initiatives.
What Investors Will Be Watching Next
The story around N A S D A Q: POM is increasingly centered on execution.
The key developments to watch include:
POMDOCTOR's latest update describes a company attempting to evolve from episodic healthcare services toward continuous, data-driven and predictive chronic disease management. Its stated architecture combines multi-source data standardization, risk identification, physician-assisted intervention and continuous AI model iteration.
The Bigger Picture for $POM
POMDOCTOR is positioning itself at the intersection of several major healthcare technology trends: artificial intelligence, remote monitoring, wearable technology, real-world data and digital healthcare services.
The company is still in an execution phase, and its forward-looking plans carry the usual risks and uncertainties associated with emerging healthcare technology businesses. POM itself cautions investors that actual results may differ materially from forward-looking expectations.
Nevertheless, the pace and breadth of the company's recent announcements make POMDOCTOR LIMITED (NAS DAQ: POM) a company with several developing catalysts to watch closely.
With AI development accelerating, RWD commercialization expanding, U.S. market preparations underway and the "hardware + AI + payment" model becoming a central part of its strategy, POM is working to build something considerably broader than a conventional online healthcare platform.
For investors following the next generation of digital healthcare infrastructure, the coming months could provide important evidence of how effectively POMDOCTOR can turn its technology, data and physician network into scalable commercial opportunities.
For more information on POM visit: https://ir.7shiliu.com/
Media Contact
Company Name: POMDOCTOR Limited (N A S D A Q: POM)
Contact Person: Zhenyang Shi, Chairman and Chief Executive Officer
Email: [email protected]
Phone: 86 020-6231 2277
Country: China
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM) | More news from this source
Press release distribution by PRLog
GUANGZHOU, China - Sept. 30, 2026 - PRLog -- POMDOCTOR LIMITED (N A S D A Q: POM) $POM is entering the final stretch of September with a rapidly developing story centered on one of healthcare technology's most closely watched opportunities: combining artificial intelligence, real-world healthcare data, connected devices, physician resources and payment infrastructure into a more continuous model of patient care.
The company's latest update adds another important layer to that strategy, highlighting continued optimization of its proprietary AI chronic disease management system, expanding applications for real-world data (RWD), and integrated in-hospital and out-of-hospital chronic disease management pilots.
For investors watching the evolving digital-health landscape, POM's recent announcements show a company attempting to move beyond the traditional online healthcare model and toward a more integrated predictive healthcare infrastructure.
The Latest Development: AI + Real-World Data
POMDOCTOR says it has completed multiple rounds of optimization of its AI chronic disease management system using multidimensional real-world healthcare data.
That data can include:
- Medication and diagnosis/treatment information
- Patient behavioral and monitoring data
- Healthcare payment information
- Physiological and remote patient monitoring data
The company's roadmap is designed around capabilities such as risk identification, personalized chronic disease intervention and physician-patient follow-up workflows. Importantly, POM describes the system as a continuing feedback loop: healthcare data generated through patient management can be processed back into the system to refine AI models and support physicians in developing increasingly personalized management strategies.
That creates a potentially significant distinction in POM's strategy. Rather than treating digital healthcare as a single online transaction, the company is working toward an ongoing data-driven relationship between patient, physician and technology.
A Four-Tier Revenue Opportunity Is Taking Shape
POM has also been emphasizing commercialization of its real-world data capabilities.
The company says its RWD initiatives include pharmaceutical real-world studies, evidence-based research cooperation, B2B healthcare data services and chronic disease management collaborations with third-party healthcare institutions.
That matters because RWD can potentially create value across multiple areas of the healthcare ecosystem. Pharmaceutical companies, healthcare providers, researchers and digital-health organizations can all have applications for properly structured healthcare information.
POM has identified pharmaceutical RWS/RWD services as a core value driver within its diversified revenue structure. The opportunity is therefore not limited to patient-facing healthcare services; it potentially extends into data-related commercial applications as well.
"Hardware + AI + Payment" Becomes a Major Theme
One of POMDOCTOR's most recent announcements, dated September 24, takes the strategy another step forward.
The company highlighted what it calls a differentiated "hardware + AI + payment" healthcare infrastructure model, with the goal of integrating continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment and fulfillment into a unified ecosystem.
The significance of this strategy is that POM is attempting to connect multiple pieces of the healthcare journey rather than concentrating on a single service.
Wearable technologies can provide health information. AI can process and analyze that information. Physicians can provide intervention and follow-up. Payment infrastructure can facilitate the financial side of healthcare services.
The company believes that connecting those components could support a more continuous and predictive healthcare model.
U.S. Expansion Adds Another Potential Catalyst
POM's strategy is also becoming increasingly international.
On August 27, the company announced that it had formally begun preparations for entry into the U.S. healthcare market. POM said it had begun recruiting U.S.-based leadership and operational personnel, assessing the U.S. market, developing a local compliance and regulatory framework, advancing product localization and engaging in exploratory discussions with potential U.S. healthcare partners.
The initial strategy is expected to emphasize pilot validation, including potential applications in remote patient monitoring and chronic disease management.
For investors, the U.S. initiative creates another development path to watch as POM works to determine how its technology and healthcare infrastructure could translate into another major healthcare market.
Investor Visibility Is Increasing
POMDOCTOR also participated in the 28th Annual H.C. Wainwright Global Investment Conference in September, with a company presentation made available to investors. The event provided another opportunity for the company to present its strategy and evolving business model to the investment community.
The timing is notable. POM is simultaneously discussing AI optimization, RWD commercialization, U.S. expansion and its broader infrastructure strategy.
That gives investors several distinct areas to monitor as the company moves forward.
Nasdaq Compliance Adds Another Important Piece
Earlier this summer, POMDOCTOR announced that it had regained compliance with Nasdaq's minimum $1.00 bid-price requirement. Nasdaq determined that POM's ADS closing bid price had remained at or above $1.00 for the required 10 consecutive business days from June 25 through July 9, 2026.
The company's ability to regain compliance removed that particular Nasdaq listing issue and allowed management to focus attention on its operating and strategic initiatives.
What Investors Will Be Watching Next
The story around N A S D A Q: POM is increasingly centered on execution.
The key developments to watch include:
- Further optimization and deployment of POM's AI chronic disease management system
- Commercialization of real-world healthcare data and pharmaceutical RWS/RWD services
- Progress from integrated in-hospital and out-of-hospital chronic disease management pilots
- Development of the company's U.S. market strategy and potential partnerships
- Expansion of the "hardware + AI + payment" infrastructure model
- Evidence of how these initiatives translate into revenue and scalable commercial operations
POMDOCTOR's latest update describes a company attempting to evolve from episodic healthcare services toward continuous, data-driven and predictive chronic disease management. Its stated architecture combines multi-source data standardization, risk identification, physician-assisted intervention and continuous AI model iteration.
The Bigger Picture for $POM
POMDOCTOR is positioning itself at the intersection of several major healthcare technology trends: artificial intelligence, remote monitoring, wearable technology, real-world data and digital healthcare services.
The company is still in an execution phase, and its forward-looking plans carry the usual risks and uncertainties associated with emerging healthcare technology businesses. POM itself cautions investors that actual results may differ materially from forward-looking expectations.
Nevertheless, the pace and breadth of the company's recent announcements make POMDOCTOR LIMITED (NAS DAQ: POM) a company with several developing catalysts to watch closely.
With AI development accelerating, RWD commercialization expanding, U.S. market preparations underway and the "hardware + AI + payment" model becoming a central part of its strategy, POM is working to build something considerably broader than a conventional online healthcare platform.
For investors following the next generation of digital healthcare infrastructure, the coming months could provide important evidence of how effectively POMDOCTOR can turn its technology, data and physician network into scalable commercial opportunities.
For more information on POM visit: https://ir.7shiliu.com/
Media Contact
Company Name: POMDOCTOR Limited (N A S D A Q: POM)
Contact Person: Zhenyang Shi, Chairman and Chief Executive Officer
Email: [email protected]
Phone: 86 020-6231 2277
Country: China
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM) | More news from this source
Press release distribution by PRLog
More News
Anthropic flags revenue surge to investors ahead of stock market debut
It comes as some investors have become concerned about the amount of money being spent on AI infrastructure.
Read more
Langflow's Critical Authenticated RCE Flaw Targeted in 1,423 Honeypot Exploit Attempts
Threat actors are exploiting a critical security flaw in Langflow, according to an alert from Previdian. Langflow is an open-source platform that allows developers to build artificial intelligence (AI) applications and agentic workflows. In February 2025, DataStax, the parent company of Langflow, was acquired by IBM. The vulnerability in question is CVE-2026-105740 (CVSS score: 9.9), a case of
Read more
Incoming calls to show caller names from November 1: What mobile users need to know
India will roll out mandatory Calling Name Presentation (CNAP) from November 1, 2026, displaying callers' names alongside phone numbers on 4G and 5G networks. Here's how the new caller ID system will work, its privacy safeguards and rules for businesses using registered names.
Read more
AhsayCBS Flaws Exploited to Deploy Web Shells Get New Fixes After Incomplete Patches
Singapore-based Ahsay Backup has released security updates to address two security flaws in AhsayCBS that have been exploited by bad actors to drop web shells and XMRig cryptocurrency miners. The vulnerabilities in question are CVE-2026-105133 and CVE-2026-105134, which could be chained to sidestep authentication and execute arbitrary commands on affected systems. In a report published earlier
Read more
ASML explores capacity expansion beyond 30% increase for 2028
Dutch semiconductor equipment maker ASML said on Wednesday that it is exploring ways to expand production capacity beyond the previously announced 30% increase planned for 2028.
Read more
China’s CXMT gets pledge of support as provincial party chief vows chip-industry expansion
Three weeks into his tenure as the Communist Party secretary of Anhui province, Li Lecheng carried out an on-site inspection at China’s home-grown memory chip giant ChangXin Memory Technologies (CXMT) on Wednesday, pledging to grow integrated circuits (ICs) as an emerging pillar industry. During the visit to the company’s headquarters in the central province’s capital of Hefei, Li urged CXMT to further refine its product portfolio and actively expand into domestic and overseas markets. He...
Read more
Palo Alto Networks Patches PAN-OS Authenticated RCE Flaw Amid Active Exploitation
Palo Alto Networks on Wednesday issued security updates for a high-severity flaw in PAN-OS software that has come under active exploitation. The vulnerability, tracked as CVE-2026-0322 (CVSS score: 8.6), is a case of remote code execution in the management interface. "A remote code execution (RCE) vulnerability in the management interface of Palo Alto Networks PAN-OS software enables an
Read more
FLÆ Robotics raises over €1 million in seed funding to develop and expand its AI hospitality agent
FLÆ Robotics, the Czech technology company behind BE-A, an AI hospitality agent, has raised over €1 million in seed funding from Purple Ventures and Garage Angels. BE-A is already used by more than 60 hotels across the United Kingdom, Germany and the Czech Republic. The company will use the investment to accelerate product development, deepen integrations with hotel systems, grow its team and expand internationally. FLÆ Robotics is strengthening its presence in Germany, expanding into Austria and building on its launch in the United Kingdom. It is also preparing to enter the U.S. hotel market.
Read more
Ecommpay adds Klarna, giving consumers a more flexible way to pay
Ecommpay, the inclusive global payments platform, has added Klarna, the everyday finance network, to its payment choices, giving merchants a simple way to offer millions of shoppers greater choice, transparency and control at checkout.
Read more
Start-up unveils prototype ‘heart’ of EUV lithography amid China chipmaking push
A Chinese start-up has unveiled a prototype extreme ultraviolet (EUV) light-source machine – a component often described as the “heart” of advanced lithography systems – marking an early but critical step in Beijing’s drive for self-reliance in chipmaking equipment. At the China International Industry Fair in Shanghai, Langdao Silex displayed its self-developed EUV light-source system. Ninety per cent of the machine’s components were localised, with the vast majority of core parts developed...
Read more
AI job losses set to rein in office demand in developed Asia-Pacific economies: report
A mild displacement of jobs across the Asia-Pacific region as companies expand their use of AI would trim five percentage points off growth in office space demand in the next few years, according to property consultancy CBRE. In a report released on Thursday it said 3.9 per cent of office jobs were vulnerable to artificial intelligence-driven displacement in developed markets in the region, including Hong Kong, Singapore, Japan, South Korea, Taiwan, Australia and New Zealand. However, only 1.7...
Read moreRecommended
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.
Copyright © 2015 - 2026 The Star Journals. All Rights Reserved.